Plasma copper and the risk of first stroke in hypertensive patients: a nested case-control study

What Was Tested

This randomized controlled trial paper looks at Copper (Supplement).

The aim of this study was to evaluate the association between plasma copper and the risk of first stroke, and examine any possible effect modifiers in hypertensive patients.

Why It Was Studied

Previous studies indicated that trace elements may play an important role in cardiovascular diseases.

However, data concerning the association between blood copper and the risk of stroke are limited.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

A total of 618 first stroke cases and 618 controls matched for age, sex, treatment group, and study site were included in this study.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.

Hypertension is defined as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg, or taking antihypertensive medication.

What Was Measured

PubMed files the paper under topics including Antihypertensive Agents, Body Mass Index, Case-Control Studies, China, Copper, Enalapril and Folic Acid.

Author keywords: first ischemic stroke, first stroke and hypertensive patients.

What This Means in Plain Language

The paper is a randomized and double-blind study of Copper (Supplement).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (The American journal of clinical nutrition), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.